US20210163957A1 - Nucleic acid for treating mite allergy - Google Patents

Nucleic acid for treating mite allergy Download PDF

Info

Publication number
US20210163957A1
US20210163957A1 US17/054,340 US201917054340A US2021163957A1 US 20210163957 A1 US20210163957 A1 US 20210163957A1 US 201917054340 A US201917054340 A US 201917054340A US 2021163957 A1 US2021163957 A1 US 2021163957A1
Authority
US
United States
Prior art keywords
der
amino acid
nucleic acid
seq
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/054,340
Other languages
English (en)
Inventor
Takanori Marui
Masao Uchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Assigned to ASTELLAS PHARMA INC. reassignment ASTELLAS PHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARUI, Takanori, UCHIDA, MASAO
Publication of US20210163957A1 publication Critical patent/US20210163957A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22065—Peptidase 1 (mite) (3.4.22.65)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Definitions

  • the present invention relates to a nucleic acid which is expected to be useful as an active ingredient of a pharmaceutical composition, for example, a nucleic acid which is expected to be useful for treating mite allergy.
  • Mite allergy is an allergic disease that occurs in response to mite-derived allergens.
  • the allergic disease is caused by the following steps: 1) allergens taken into a body are phagocytosed by antigen-presenting cells and presented to naive T cells, 2) the naive T cells are differentiated into Th2 cells, 3) cytokine such as IL-4 is produced from an immune cell such as the Th2 cell, 4) B cells produce IgE by IL-4, and 5) IgE binding to the allergens binds to mast cells.
  • Th1-type immunity involving Th1 cells producing IFN- ⁇ or the like
  • Th2-type immunity involving Th2 cells producing IL-4 or the like shifts to Th2-type dominant which results in Th2-type inflammatory immune response
  • IFN- ⁇ can be used as an indicator of Th1-type immunity
  • IL-4 can be used as an indicator of Th2-type immunity.
  • IFN- ⁇ causes a preferential class switch to IgG2a isotype in activated B cells, while suppresses responses to all the other isotypes. That is, IgG2a can also be used as an indicator of Th1-type immunity.
  • IgG2a production of IgG2a is promoted in IL-4-deficient mice and that IgG2a production is suppressed in IFN- ⁇ -deficient mice (Arthritis Res., 2002, Vol. 4, p. 54-58).
  • antibodies produced from B cells are involved in the mechanism of action of allergen immunotherapy.
  • IgG antagonizes IgE binding to an allergen to inhibit formation of allergen-IgE complex and thereby inhibit histamine release from mast cells (J Allergy Clin Immunol., 2017, Vol. 140, p. 1485-1498).
  • nucleic acid vaccines for treating allergy using lysosome-associated membrane proteins (LAMP) have been studied.
  • a plasmid comprising a nucleic acid encoding a chimeric protein comprising LAMP-1, which is a member of LAMP family, and Cry J1 and/or Cry J2, which are allergens of Cryptomeria japonica , was constructed (Patent Document 3 and Non-Patent Document 2). It has been reported that such a plasmid does not cause systemic release of free allergen which causes anaphylaxis, but induces a Th1-type immune response.
  • a plasmid comprising a nucleic acid encoding a chimeric protein comprising LAMP-1 and peanut allergens Ara H1, Ara H2 and Ara H3 reduced production of IgE in a mouse model
  • Patent Document 4 a vaccine comprising a nucleic acid encoding a chimeric protein comprising Der p 1 and a transmembrane domain of LAMP-1 and an endosomal/lysosomal targeting domain has been constructed (Patent Document 5 and Non-Patent Document 3).
  • a nucleic acid vaccine for treating mite allergy comprising multiple mite allergen antigens, and an intra-organelle stabilizing domain of LAMP-1 and an endosomal/lysosomal targeting domain has not been reported.
  • An object of the present invention is to provide a nucleic acid which is expected to be useful for treating mite allergy.
  • the present inventors have prepared LAMP-Der p 1-Der p 2-Der p 23-Der p 7 plasmid (Example 1), confirmed that a chimeric protein is expressed from the plasmid (Example 2), and found that a Th1-type immune response is induced in mice to which the plasmid is administered (Examples 3 and 4).
  • a nucleic acid which is expected to be useful for treating mite allergy is provided, and thereby the present invention has been completed.
  • the present invention relates to the following [1] to [17].
  • a nucleic acid comprising:
  • nucleotide sequence encoding a chimeric protein
  • nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP.
  • a nucleic acid comprising:
  • nucleotide sequence encoding a chimeric protein
  • nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP.
  • the signal peptide consists of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2
  • the intra-organelle stabilizing domain consists of an amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2
  • the allergen domain is an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2
  • Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2
  • Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2
  • Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2
  • the transmembrane domain consists of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2
  • the endosomal/lysosomal targeting domain consists of the an amino acid sequence of amino acid numbers 1037 to 1040
  • a nucleic acid comprising:
  • nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence having at least 90% identity to the amino acid sequence shown by SEQ ID NO: 2, wherein the nucleic acid has an action of inducing Th1-type immunity to an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7.
  • a nucleic acid comprising:
  • nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2;
  • nucleic acid has an action of inducing Th1-type immunity to an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7.
  • a nucleic acid comprising:
  • nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence shown by SEQ ID NO: 2.
  • An expression vector comprising:
  • An expression vector comprising:
  • a method for producing a nucleic acid comprising:
  • a pharmaceutical composition comprising:
  • the pharmaceutical composition described in [13] which is a pharmaceutical composition for preventing or treating mite allergy.
  • a method for preventing or treating mite allergy comprising:
  • the nucleic acid of the present invention can be used for preventing or treating mite allergy.
  • FIG. 1 is a diagram illustrating production of IgG2a specific to Der p 1, Der p 2, Der p 23, and Der p 7, which is induced when the nucleic acid of the present invention is administered to a mouse.
  • the vertical axis indicates absorbance at 450 nm, and the horizontal axis indicates each administration group.
  • the horizontal lines indicate arithmetic mean values.
  • FIG. 2 illustrates IFN- ⁇ production when spleen cells of mice to which the nucleic acid of the present invention has been administered were stimulated with Der p 1 protein, Der p 2 protein, Der p 7 protein, or Der p 23 protein.
  • the vertical axis indicates the concentration of IFN- ⁇ in the culture supernatant (pg/mL), and the horizontal axis indicates each administration group.
  • the horizontal lines indicate arithmetic mean values.
  • the dotted line indicates the value of lower limit of detection (LLOD).
  • FIG. 3 illustrates IL-4 production when spleen cells of mice to which the nucleic acid of the present invention has been administered were stimulated with Der p 1 protein, Der p 2 protein, Der p 7 protein, or Der p 23 protein.
  • the vertical axis indicates the concentration of IL-4 in the culture supernatant (pg/mL), and the horizontal axis indicates each administration group.
  • the horizontal lines indicate arithmetic mean values.
  • the dotted line indicates the value of lower limit of detection (LLOD).
  • nucleic acid of the present invention examples include a nucleic acid having the following features:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP.
  • the nucleic acid is a polymer which is formed by polymerization of nucleotides and consists of a nucleotide sequence with an arbitrary length.
  • the nucleotides can include deoxyribonucleotides, ribonucleotides, and/or their analogs.
  • the nucleic acid of the present invention is DNA, RNA or modified a nucleic acid thereof. In one embodiment, the nucleic acid of the present invention is DNA.
  • the nucleic acid of the present invention is a nucleic acid introduced into an expression vector. In one embodiment, the nucleic acid of the present invention is a nucleic acid introduced into a plasmid vector.
  • chimeric protein means a protein encoded by a nucleotide sequence in which two or more genes are fused by using genetic recombination technology.
  • the nucleic acid of the present invention includes a nucleotide sequence encoding chimeric protein comprising a signal peptide, an intra-organelle stabilizing domain of LAMP, an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a transmembrane domain, and an endosomal/lysosomal targeting domain of LAMP in this order (hereinafter, referred to as “chimeric protein relating to the present invention”).
  • LAMP is well-known protein to those skilled in the art (J Biol Chem., 1991, Vol. 266, p. 21327-21330).
  • LAMP is not particularly limited, but examples thereof include LAMP-1, LAMP-2, CD63/LAMP-3, DC-LAMP, and LIMP II, and homologs, orthologs, paralogs, variants, and modified proteins thereof.
  • LAMP is LAMP-1.
  • an animal from which LAMP is derived is not particularly limited, but in one embodiment, LAMP is human LAMP.
  • human LAMP is human LAMP-1.
  • Examples of an amino acid sequence of human LAMP-1 include an amino acid sequence in which the amino acid sequence shown by amino acid numbers 1005 to 1040 of SEQ ID NO: 2 is bound to a C-terminal of the amino acid sequence shown by amino acid numbers 1 to 380 of SEQ ID NO: 2.
  • the general structure of the signal peptide is well known to those skilled in the art (Annu Rev Biochem., 2003, Vol. 72, p. 395 to 447).
  • the signal peptide has a function of directing transport and localization of a protein.
  • any suitable signal peptide can be selected as long as it has a function of directing transport and localization of the protein.
  • the signal peptide used in the present invention is a signal peptide of LAMP.
  • the signal peptide of LAMP used in the present invention is a signal peptide of LAMP-1.
  • the signal peptide used in the present invention consists of the following amino acid sequence of (a) or (b):
  • identity in the present specification means a value of Identity obtained by using an EMBOSS Needle (Nucleic Acids Res., 2015, Vol. 43, p. W580-W584; https://www.ebi.ac.uk/Tools/psa/embossneedle/) with a parameter prepared by default.
  • EMBOSS Needle Nucleic Acids Res., 2015, Vol. 43, p. W580-W584; https://www.ebi.ac.uk/Tools/psa/embossneedle/
  • the signal peptide used in the present invention consists of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2.
  • the sequence of the intra-organelle stabilizing domain of LAMP is well known to those skilled in the art (WO 2013/187906).
  • the intra-organelle stabilizing domain of LAMP is well known to those skilled in the art (WO 2013/187906).
  • the intra-organelle stabilizing domain of LAMP is well known to those skilled in the art (WO 2013/187906).
  • LAMP has a function of protecting the allergen domain from proteases, low pH, and other substances and conditions that destabilize a protein.
  • any suitable intra-organelle stabilizing domain of LAMP can be selected as long as it has a function of protecting the allergen domain from proteases, low pH, and other substances and conditions that destabilize a protein.
  • the intra-organelle stabilizing domain of LAMP used in the present invention is an intra-organelle stabilizing domain of LAMP-1.
  • the intra-organelle stabilizing domain of LAMP used in the present invention consists of the following amino acid sequence of (a) or (b):
  • the intra-organelle stabilizing domain of LAMP used in the present invention consists of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2.
  • the allergen domain used in the present invention includes Der p 1, Der p 2, Der p 23, and Der p 7 as allergens.
  • Der p 1, Der p 2, Der p 23, and Der p 7 are allergens that can be observed in mites (WO 1988/010297; WO 2007/124524; and Clin Exp Allergy., 1995, Vol. 25, p. 416-422).
  • Der p 1, Der p 2, Der p 23, and Der p 7 used in the present invention may be variants thereof as long as they have antigenicity.
  • the antigenicity of any protein can be confirmed, for example, by observing that administration to an animal elicits antibody production or T cell response to that protein (Bioanalysis., 2012, Vol. 4, p. 397-406).
  • Der p 1, Der p 2, Der p 23, and Der p 7 used in the present invention lack the signal peptide.
  • Der p 1 consists of the following amino acid sequence of (a) or (b):
  • Der p 1 consists of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2.
  • Der p 2 consists of the following amino acid sequence of (a) or (b):
  • Der p 2 consists of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2.
  • Der p 23 consists of the following amino acid sequence of (a) or (b):
  • Der p 23 consists of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2.
  • Der p 7 consists of the following amino acid sequence of (a) or (b):
  • Der p 7 consists of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2.
  • the allergen domain used in the present invention comprises Der p 1, Der p 2, Der p 23, and Der p 7 in any order.
  • the allergen domain used in the present invention comprises Der p 1, Der p 2, Der p 23, and Der p 7 in this order.
  • the allergen domain used in the present invention consists of the amino acid sequence of amino acid numbers 383 to 1002 of SEQ ID NO: 2.
  • the general structure of the transmembrane domain is well known to those skilled in the art (Annu Rev Biochem., 2007, Vol. 76, p. 125 to 140).
  • the transmembrane domain has a function of anchoring proteins to biological membranes.
  • any suitable transmembrane domain protein can be selected as long as it has a function of anchoring proteins to biological membranes.
  • the transmembrane domain used in the present invention is a transmembrane domain of LAMP.
  • the transmembrane domain of LAMP used in the present invention is a transmembrane domain of LAMP-1.
  • the transmembrane domain used in the present invention consists of the following amino acid sequence of (a) or (b):
  • the transmembrane domain used in the present invention consists of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2.
  • the structure of the endosomal/lysosomal targeting domain of LAMP is well known to those skilled in the art (WO 1994/017192).
  • the endosomal/lysosomal targeting domain of LAMP has a function of transporting a protein to lysosome.
  • any suitable endosomal/lysosomal targeting domain of LAMP can be selected as long as it has a function of transporting the protein to lysosome.
  • endosomal/lysosomal targeting domain of LAMP used in the present invention is an endosomal/lysosomal targeting domain of LAMP-1.
  • the endosomal/lysosomal targeting domain of LAMP used in the present invention consists of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2, or an amino acid sequence in which 1 amino acid is deleted, substituted, inserted and/or added in the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the endosomal/lysosomal targeting domain of LAMP used in the present invention consists of an amino acid sequence in a range of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the signal peptide, the intra-organelle stabilizing domain of LAMP, each allergen comprised in the allergen domain, the transmembrane domain, and the endosomal/lysosomal targeting domain of LAMP may be directly linked or may be indirectly linked via a linker peptide.
  • the linker peptide to be used can be appropriately selected by those skilled in the art. In one embodiment, the linker peptide consists of 10 or less amino acids.
  • a linker peptide used between the intra-organelle stabilizing domain of LAMP and the allergen domain, between allergens, and between the allergen domain and the transmembrane domain is a linker peptide selected from the group consisting of LeuGlu, GlyGlyGlyGly, and GluPheThr.
  • the linker peptide used between the transmembrane domain and the endosomal/lysosomal targeting domain of LAMP is a linker peptide consisting of the amino acid sequence of amino acid numbers 1029 to 1036 of SEQ ID NO: 2.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain the of LAMP-1.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2,
  • Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2
  • Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2,
  • nucleotide sequence encoding a peptide linker consisting of the amino acid sequence of amino acid numbers 1029 to 1036 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP-1.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2 in this order,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2 in this order,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2,
  • nucleotide sequence encoding a peptide linker consisting of the amino acid sequence of amino acid numbers 1029 to 1036 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the nucleic acid of the present invention is not particularly limited as long as it encodes the chimeric protein relating to the present invention, and has an action of inducing Th1-type immunity with respect to the allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7, when the nucleic acid is administered to a human or an animal.
  • the nucleic acid of the present invention may be a nucleic acid having an action of inducing Th1 cell dominant immune response, when the nucleic acid is administered to a human or an animal.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence having at least 90%, 92%, 94%, 96%, 98%, or 99% identity to the amino acid sequence shown by SEQ ID NO: 2.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence having at least 90% identity to the amino acid sequence shown by SEQ ID NO: 2.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2, or a chimeric protein consisting of an amino acid sequence in which 1 to 10 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence shown by SEQ ID NO: 2.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence having at least 90% identity to the amino acid sequence shown by SEQ ID NO: 2,
  • nucleic acid has an action of inducing Th1-type immunity to the allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2 or
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence in which 1 to 10 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence shown by SEQ ID NO: 2, wherein the nucleic acid has an action of inducing Th1-type immunity to an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence having at least 90% identity to the amino acid sequence shown by SEQ ID NO: 2, wherein the nucleic acid has an action of inducing Th1-type immunity to Der p 1, Der p 2, Der p 23, and Der p 7.
  • nucleic acid of the present invention is the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2 or
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence in which 1 to 10 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence shown by SEQ ID NO: 2, wherein the nucleic acid has an action of inducing Th1-type immunity to Der p 1, Der p 2, Der p 23, and Der p 7.
  • nucleic acid of the present invention is the following nucleic acids
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2.
  • the nucleotide sequence encoding the chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2 means the nucleotide sequence shown by SEQ ID NO: 1.
  • the nucleic acid of the present invention can be easily prepared by those skilled in the art by using methods known in the art.
  • the nucleic acid of the present invention can be synthesized by using gene synthesis methods known in the art.
  • gene synthesis methods such as a method for synthesizing an antibody gene described in WO 90/07861 can be used.
  • the nucleic acid of the present invention can be easily replicated by those skilled in the art using methods known in the art.
  • the nucleic acid of the present invention can be replicated by the method described later in ⁇ Method for producing the nucleic acid of the present invention and nucleic acid which can be produced by the method>.
  • the expression vector of the present invention includes an expression vector comprising the nucleic acid of the present invention.
  • the expression vector used to express a chimeric protein from the nucleic acid of the present invention is not particularly limited as long as it can express the chimeric protein from the nucleic acid of the present invention in the animal cells.
  • the expression vector used to express a chimeric protein from the nucleic acid of the present invention is an expression vector which can be used for expressing the chimeric protein in a human body.
  • the expression vector used in the present invention include a plasmid vector, a viral vector (for example, adenovirus, retrovirus, adeno-associated virus) and the like.
  • the expression vector of the present invention is a plasmid vector.
  • “plasmid” means the plasmid vector.
  • the expression vector of the present invention may comprise a promoter operably linked to the nucleic acid of the present invention.
  • the promoter for expressing the chimeric protein from the nucleic acid of the present invention in animal cells include a virus-derived promoter such as CMV (cytomegalovirus), RSV (respiratory syncytial virus), and SV40 (simian virus 40), an actin promoter, EF (elongation factor) 1 ⁇ promoter, a heat shock promoter and the like.
  • the promoter comprised in the expression vector of the present invention is a CMV promoter.
  • the expression vector of the present invention may comprise a start codon and a stop codon. In this case, an enhancer sequence, an untranslated region, a splicing junction, a polyadenylation site, or a replicable unit may be comprised.
  • the expression vector of the present invention is an expression vector comprising the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the expression vector of the present invention is an expression vector comprising the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2,
  • nucleotide sequence encoding a peptide linker consisting of the amino acid sequence of amino acid numbers 1029 to 1036 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the expression vector of the present invention is an expression vector comprising the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2 in this order,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the expression vector of the present invention is an expression vector comprising the following nucleic acid:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2 in this order,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2,
  • nucleotide sequence encoding a peptide linker consisting of the amino acid sequence of amino acid numbers 1029 to 1036 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the expression vector of the present invention is an expression vector comprising a nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2.
  • the expression vector of the present invention is an expression vector comprising a nucleic acid comprising the nucleotide sequence shown by SEQ ID NO: 1.
  • the expression vector of the present invention is an expression vector comprising a nucleic acid consisting of the nucleotide sequence shown by SEQ ID NO: 3.
  • the host cell of the present invention includes a host cell transformed with the nucleic acid of the present invention. In one embodiment, the host cell of the present invention is a host cell transformed with the expression vector of the present invention. In one embodiment, the host cell of the present invention is a host cell transformed with the expression vector of the present invention which is a plasmid vector.
  • the host cell transformed with the nucleic acid of the present invention is not particularly limited, and any cell known in the art can be selected as long as it is a cell that can be used for nucleic acid replication.
  • Examples of the host cell that can be used for nucleic acid replication include various cells such as natural cells or artificially established cells commonly used in the technical field of the present invention (for example, animal cells (for example, CHOK1SV cells), insect cells (for example, Sf9), bacteria (for example, E. coli ), and yeasts (for example, Saccharomyces and Pichia )).
  • E. coli can be used as a host cell. Transformation itself can be carried out by known methods.
  • Examples of the method for producing the nucleic acid of the present invention include a method for producing a nucleic acid or an expression vector, which comprises a step of culturing host cells transformed with the nucleic acid or the expression vector of the present invention.
  • the method for producing the nucleic acid of the present invention comprises a step of culturing the host cell transformed with the nucleic acid of the present invention, and replicating the nucleic acid of the present invention.
  • the method for producing the nucleic acid of the present invention comprises a step of culturing the host cell transformed with the expression vector of the present invention, and replicating the expression vector of the present invention.
  • the host cell used in the method for producing the nucleic acid of the present invention is E. coli .
  • an appropriate culture medium such as LB medium, M9 medium, Terrific Broth medium, SOB medium, SOC medium, or 2 ⁇ YT medium can be selected.
  • the culturing of E. coli can be carried out in an environment where carbon (it is not particularly limited as long as it is an assimilable carbon compound; for example, polyols such as glycerin, or organic acids such as pyruvic acid, succinic acid, or citric acid), nitrogen (it is not particularly limited as long as it is a nitrogen compound that can be used by E.
  • control of culturing includes control of parameters such as pH, temperature, stir, air flow and dissolved oxygen.
  • the conditions of culturing include pH of 6.7 to 7.5, temperature of 20° C. to 37° C., and a stirring speed of 200 to 300 rpm.
  • the method for producing the nucleic acid of the present invention may comprise a step of obtaining lysate from collected culture solutions.
  • the lysate can be obtained, for example, by treating the collected culture solutions with an alkaline lysis method or boiling method.
  • the step of obtaining the lysate may include a step of sterile filtration of a final lysate material.
  • the method for producing the nucleic acid of the present invention may further comprise a step of purifying nucleic acid or an expression vector from lysate.
  • Ion exchange chromatography and/or hydrophobic interaction chromatography can be used to purify the nucleic acid or the expression vector from the lysate.
  • the step of purifying the nucleic acid or the expression vector from the lysate may include a step of ultrafiltration and/or diafiltration.
  • a sterile filtration step may be comprised as a final treatment of the purification step.
  • the nucleic acid of the present invention is a nucleic acid produced by the method for producing the nucleic acid of the present invention.
  • the expression vector of the present invention is an expression vector produced by the method for producing the nucleic acid of the present invention.
  • the pharmaceutical composition of the present invention includes a pharmaceutical composition comprising the nucleic acid of the present invention and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition comprising the vector of the present invention and the pharmaceutically acceptable excipient.
  • the pharmaceutical composition of the present invention can be prepared by a generally used method with an excipient generally used in the field, that is, a pharmaceutical excipient, a pharmaceutical carrier or the like. Examples of dosage forms of these pharmaceutical compositions include, for example, parenteral agents such as injections and drip agents, which can be administered by intravenous administration, subcutaneous administration, intradermal administration, and intramuscular administration. In formulating, excipients, carriers, additives, and the like can be used according to these dosage forms within the pharmaceutically acceptable range.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition comprising the nucleic acid or the expression vector of the present invention and the pharmaceutically acceptable excipient.
  • the administration amount of the nucleic acid of the present invention or the expression vector varies depending on the degree of symptoms and age of the patient, and the dosage form of the preparation used, for example, the amount in a range of 0.001 mg/kg to 100 mg/kg can be used. Further, it is possible to prepare a formulation by adding the nucleic acid or the expression vector of the present invention in an amount corresponding to such administration amount.
  • the pharmaceutical composition of the present invention can be used as an agent for preventing or treating allergy caused by an allergen selected from Der p 1, Der p 2, Der p 23, and Der p 7. Further, the pharmaceutical composition of the present invention can be used as an agent for prevention or treating the mite allergy.
  • the present invention includes a pharmaceutical composition for preventing or treating allergy, comprising the nucleic acid of the present invention.
  • the present invention includes a method for preventing or treating allergy, comprising administering a prophylactically effective or therapeutically effective amount of the nucleic acid of the present invention.
  • the present invention also includes the nucleic acid of the present invention for use in preventing or treating allergy.
  • the present invention includes use of the nucleic acid of the present invention for the manufacture of a pharmaceutical composition for preventing or treating allergy.
  • the above-described allergy is allergy caused by an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7.
  • the above-described allergy is allergy affecting an allergy patient having an antibody that responds to an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7. Further, in one embodiment, the above-described allergy is mite allergy.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition for preventing or treating allergy, comprising the following nucleic acid and a pharmaceutically acceptable excipient:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition for preventing or treating allergy, comprising the following nucleic acid and a pharmaceutically acceptable excipient:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2 in this order,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition for preventing or treating allergy, comprising a nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2 and a pharmaceutically acceptable excipient.
  • the present invention includes a pharmaceutical composition for preventing or treating allergy, comprising the expression vector of the present invention.
  • the present invention includes a method for preventing or treating allergy, comprising administering a prophylactically effective or therapeutically effective amount of the expression vector of the present invention.
  • the present invention also includes the expression vector of the present invention for use in preventing or treating allergy.
  • the present invention includes use of the expression vector of the present invention for the manufacture of a pharmaceutical composition for preventing or treating allergy.
  • the above-described allergy is allergy caused by an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7.
  • the above-described allergy is allergy affecting an allergy patient having an antibody that responds to an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7. Further, in one embodiment, the above-described allergy is mite allergy.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition for preventing or treating allergy, comprising an expression vector comprising the following nucleic acid and a pharmaceutically acceptable excipient:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition for preventing or treating allergy, comprising an expression vector comprising the following nucleic acid and a pharmaceutically acceptable excipient:
  • nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleotide sequence is a nucleotide sequence comprising the following nucleotide sequences in this order:
  • nucleotide sequence encoding a signal peptide consisting of the amino acid sequence of amino acid numbers 1 to 27 of SEQ ID NO: 2,
  • nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP consisting of the amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2,
  • a nucleotide sequence encoding an allergen domain comprising Der p 1 consisting of the amino acid sequence of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2, and Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2 in this order,
  • nucleotide sequence encoding a transmembrane domain consisting of the amino acid sequence of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and
  • nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP consisting of the amino acid sequence of amino acid numbers 1037 to 1040 of SEQ ID NO: 2.
  • the pharmaceutical composition of the present invention is a pharmaceutical composition for preventing or treating allergy, comprising an expression vector comprising a nucleic acid comprising a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2 and a pharmaceutically acceptable excipient.
  • LAMP-Der p 1-Der p 2-Der p 23-Der p 7 plasmid consisting of the nucleotide sequence shown by SEQ ID NO: 3 an expression vector comprising a nucleic acid comprising a nucleotide sequence comprising the following nucleotide sequences in this order (that is, a nucleotide sequence encoding a chimeric protein consisting of the amino acid sequence shown by SEQ ID NO: 2): a nucleotide sequence encoding a signal peptide of LAMP-1 (the amino acid sequence of 1 to 27 of SEQ ID NO: 2), a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP-1 (the amino acid sequence of 28 to 380 of SEQ ID NO: 2), a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7 in this order (the amino acid sequence of 383 to 1002 of SEQ ID NO: 2),
  • the plasmid can be constructed by inserting synthetic DNA, in which Xho I recognition sequence is added to 5′ end of the nucleotide sequence of 1147 to 3006 of SEQ ID NO: 1 (a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7 in this order) and Eco RI recognition sequence is added to the 3′ end of the nucleic acid sequence, into Eco RI-Xho I site of the plasmid shown by SEQ ID NO: 6 of Japanese Patent No. 5807994.
  • E. coli was transformed with the constructed LAMP-Der p 1-Der p 2-Der p 23-Der p 7 plasmid and cultured in a liquid medium.
  • the amplified LAMP-Der p 1-Der p 2-Der p 23-Der p 7 plasmid was obtained by a method of centrifuging the culture solution and collecting the cells based on a general plasmid extraction and purification method (miniprep method).
  • Human fetal kidney-derived 293T cells (Thermo Fisher Scientific, Cat. HCL4517) were seeded in 6-well plates (Cat. 3810-006 manufactured by IWAKI) at 3 ⁇ 10 5 cells/well in D-MEM medium (Sigma-Aldrich, Cat. D5796) containing 10% fetal bovine serum (Hyclone, Cat. SH30070.03) and 100-fold diluted penicillin-streptomycin (Thermo Fisher Scientific, Cat. 15070063). After overnight culture of the seeded cells at 37° C.
  • Pretreatment Cells were lysed in RIPA buffer (Pierce, Cat. 89900) containing a protease inhibitor (Sigma-Aldrich, Cat. 1873580), and the protein concentration of the supernatant after centrifugation at 20,000 ⁇ g for 5 minutes was measured.
  • RIPA buffer Pulierce, Cat. 89900
  • a protease inhibitor Sigma-Aldrich, Cat. 1873580
  • Blotting was performed by bringing PVDF membrane (Thermo Fisher Scientific, Cat. LC2005) into contact with the gel after SDS-PAGE, and electrifying for 90 minutes at 180 mA in XCell II Blot Module (Thermo Fisher Scientific, Cat. EI9051) filled with NuPAGE (Registered trademark) Transfer buffer (Thermo Fisher Scientific, Cat. NP0006) containing 20% of methanol.
  • Blocking The membrane after electrification was immersed in Blocking One (Nacalai Tesque, Cat. 03953-95) and shaken at room temperature for one hour.
  • Anti-human LAMP-1 antibody (Sino biological, Cat. 11215-RP01) was added at 1000-fold dilution in TBS Tween-20 buffer (Thermo Fisher Scientific, Cat. 28360) containing 10% of Blocking One. The membrane was immersed in this buffer and shaken overnight at 4° C.
  • the membrane was washed with TBS Tween-20 buffer.
  • Anti-rabbit IgG (H+L chain) pAb-HRP (MBL, Cat. 458) was added at 3000-fold dilution in TBS Tween-20 buffer containing 10% of Blocking One.
  • the membrane was immersed in this buffer and shaken at room temperature for one hour.
  • Detection The membrane was washed with TBS Tween-20 buffer. The membrane was immersed in ECL prime western blotting detection reagent (GE Healthcare, Cat. RPN2232), and an image was detected with LumiVision PRO 400EX (Aisin Seiki Co., Ltd.). In the image, a band responsive to the anti-human LAMP-1 antibody corresponding to the chimeric protein was detected.
  • LAMP-Der p 1-Der p 2-Der p 23-Der p 7 chimeric protein in the cell was expressed by introducing the LAMP-Der p 1-Der p 2-Der p 23-Der p 7 plasmid to the human fetal kidney-derived 293T cell line.
  • LAMP-Der p 23-Der p 7-Der p 2-Der p 1 plasmid an expression vector comprising a nucleic acid comprising a nucleotide sequence comprising the following nucleotide sequences in this order: a nucleotide sequence encoding the amino acid sequence of amino acid numbers 1 to 380 of SEQ ID NO: 2 (hereinafter, refer to as N-terminal of LAMP-1 in Examples 3 and 4), a nucleotide sequence encoding an allergen domain comprising Der p 23 consisting of the amino acid sequence of amino acid numbers 732 to 800 of SEQ ID NO: 2 (hereinafter, refer to as Der p 23 domain in Examples 3 and 4), Der p 7 consisting of the amino acid sequence of amino acid numbers 805 to 1002 of SEQ ID NO: 2 (hereinafter, refer to as Der p 7 domain in Examples 3 and 4), Der p 2 consisting of the amino acid sequence of amino acid numbers 599 to 727 of SEQ ID
  • Each control plasmid can be prepared by the same method as the method described in Example 1. To mice, 25 ⁇ L of PBS solution containing 50 ⁇ g of the above plasmid or the above plasmid mixture or 25 ⁇ L of PBS was administered. An antibody titer was measured by ELISA using a 100-fold or 1000-fold diluted plasma sample, and the absorbance at 450 nm was measured. ELISA measurement was performed based on a general ELISA method using F96 MAXISORP NUNC-IMMUNO PLATE (Nunc, Cat. 439454) as a test plate.
  • Der p 1 which is a purified protein (Indoor biotechnologies, NA-DP1-1, lot: 38052), Der p 2 which is a purified protein (Indoor biotechnologies, NA-DP2-1, lot: 36118), Der p 7 which is a recombinant purified protein (Indoor biotechnologies, RP-DP7-1, lot: 34033), or Der p 23 which is a recombinant purified protein (Sysmex, UniProtKB: A0A0K2DQU8) is prepared to 1 ⁇ g/mL with PBS, added at 50 ⁇ L/well and allowed to stand overnight at 4° C.
  • washing buffer PBS Tween-20 buffer; Thermo Fisher Scientific, Cat. 28352
  • 100 ⁇ L/well of PBS containing 1% of BSA Sigma-Aldrich, Cat. A8022
  • 50 ⁇ L/well of a 100-fold or 1000-fold diluted plasma sample in PBS containing 1% of BSA was added and allowed to stand at room temperature for one hour.
  • 50 ⁇ L/well of a 50000-fold diluted secondary antibody Goat anti-mouse IgG2a HRP Conjugated (Bethyl Laboratories, Cat.
  • splenocytes were prepared according to a general method from the mice used in Example 3 and the mice administered with a control plasmid (an expression vector comprising a nucleic acid comprising a nucleotide sequence comprising the following nucleotide sequences in this order: a nucleotide sequence encoding N-terminal of LAMP-1 and a nucleotide sequence encoding C-terminal of LAMP-1) with the same protocol as in Example 3 on Day 63.
  • a control plasmid an expression vector comprising a nucleic acid comprising a nucleotide sequence comprising the following nucleotide sequences in this order: a nucleotide sequence encoding N-terminal of LAMP-1 and a nucleotide sequence encoding C-terminal of LAMP-1
  • the control plasmid can be prepared by deleting Eco RI-Xho I site of the plasmid shown by SEQ ID NO: 6 of Japanese Patent No. 5807994.
  • Splenocytes were seeded in 96-well plates (Cat. 3860-096 manufactured by IWAKI) at 8 ⁇ 10 5 cells/well in RPMI-1640 medium (Sigma-Aldrich, Cat. R8758) containing 10% fetal bovine serum (Hyclone, Cat. SH30070.03) and 100-fold diluted penicillin-streptomycin (ThermoFisher Scientific, Cat. 15070063).
  • Der p 1 Indoor biotechnologies, NA-DP1-1, lot: 38052
  • Der p 2 Indoor biotechnologies, NA-DP2-1, lot: 36118
  • Der p 7 Indoor biotechnologies, RP-DP7-1, lot: 34033
  • Der p 23 Sysmex, UniProtKB: A0A0K2DQU8
  • Culturing was performed at 37° C. under 5% of CO 2 for 72 hours.
  • the concentrations of IFN- ⁇ and IL-4 in the culture supernatant were measured by ELISA method.
  • a supernatant sample diluted 10-fold with TBS containing 0.1% BSA and 0.05% Tween 20 was used for the measurement of IFN- ⁇ , and a supernatant undiluted sample was used for the measurement of IL-4.
  • F96 MAXISORP NUNC-IMMUNO PLATE (Nunc, Cat. 439454) was used as a test plate for ELISA measurement. The measurement was carried out using mouse IFN- ⁇ DuoSet ELISA (R&D Systems, Cat. DY485) and mouse IL-4 DuoSet ELISA (R&D Systems, Cat. DY 404) according to attached protocol.
  • LAMP-Der p 23-Der p 7-Der p 2-Der p 1 plasmid (Der p23-p7-p2-p1)
  • a mixture of LAMP-Der p 1-Der p 2 plasmid and LAMP-Der p 23-Der p 7 plasmid (Der p1-p2+Der p23-p7)
  • a mixture of LAMP-Der p 1 plasmid, LAMP-Der p 2 plasmid, LAMP-Der p 7 plasmid, and LAMP-Der p 23 plasmid (4 plasmid mix) were administered to the mice three times, comparable mite-derived allergen-specific IFN- ⁇ production was induced.
  • the nucleic acid of the present invention is expected to be useful for the prevention or treatment of mite allergy.
  • the method for producing the nucleic acid of the present invention is useful for producing the nucleic acid.
  • nucleotide sequence shown by SEQ ID NO: 1 in the sequence listing is a nucleotide sequence encoding LAMP-Der p 1-Der p 2-Der p 23-Der p 7 chimeric protein
  • amino acid sequence shown by SEQ ID NO: 2 in the sequence listing is the amino acid sequence encoded by SEQ ID NO: 1.
  • nucleotide sequence shown by SEQ ID NO: 3 is the nucleotide sequence of LAMP-Der p 1-Der p 2-Der p 23-Der p 7 plasmid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Insects & Arthropods (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
US17/054,340 2018-05-11 2019-05-10 Nucleic acid for treating mite allergy Abandoned US20210163957A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-091963 2018-05-11
JP2018091963 2018-05-11
PCT/JP2019/018657 WO2019216394A1 (ja) 2018-05-11 2019-05-10 ダニアレルギー治療のための核酸

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/018657 A-371-Of-International WO2019216394A1 (ja) 2018-05-11 2019-05-10 ダニアレルギー治療のための核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/377,297 Continuation US11312966B2 (en) 2018-05-11 2021-07-15 Nucleic acid for treating mite allergy

Publications (1)

Publication Number Publication Date
US20210163957A1 true US20210163957A1 (en) 2021-06-03

Family

ID=68468077

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/054,340 Abandoned US20210163957A1 (en) 2018-05-11 2019-05-10 Nucleic acid for treating mite allergy
US17/377,297 Active US11312966B2 (en) 2018-05-11 2021-07-15 Nucleic acid for treating mite allergy

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/377,297 Active US11312966B2 (en) 2018-05-11 2021-07-15 Nucleic acid for treating mite allergy

Country Status (18)

Country Link
US (2) US20210163957A1 (ja)
EP (1) EP3795688A4 (ja)
JP (1) JPWO2019216394A1 (ja)
KR (1) KR20210007977A (ja)
CN (1) CN112105735A (ja)
AR (1) AR115379A1 (ja)
AU (1) AU2019268022A1 (ja)
BR (1) BR112020023041A2 (ja)
CA (1) CA3099495A1 (ja)
CO (1) CO2020013967A2 (ja)
JO (1) JOP20200285A1 (ja)
MA (1) MA52634A (ja)
MX (1) MX2020012057A (ja)
PH (1) PH12020551876A1 (ja)
SG (1) SG11202011163SA (ja)
TW (1) TW202003542A (ja)
WO (1) WO2019216394A1 (ja)
ZA (1) ZA202006984B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019268022A1 (en) * 2018-05-11 2020-11-26 Astellas Pharma Inc. Nucleic acid for treating mite allergy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312966B2 (en) * 2018-05-11 2022-04-26 Astellas Pharma Inc. Nucleic acid for treating mite allergy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587994B2 (ja) 1977-09-22 1983-02-14 エプソン株式会社 液晶表示装置
KR900002146B1 (ko) 1987-02-27 1990-04-02 금성전선 주식회사 소형흡수 냉온수기 자동 추기 장치
JP2993967B2 (ja) 1987-06-17 1999-12-27 インスティテュート・フォー・チャイルド・ヘルス・リサーチ ダニアレルゲンのクローニング
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP2004083812A (ja) 2002-08-28 2004-03-18 Catalysts & Chem Ind Co Ltd 透明被膜形成用塗布液および透明被膜付基材、表示装置
AU2003256240A1 (en) 2002-08-29 2004-03-19 National University Of Singapore Recombinant nucleic acid useful for inducing protective immune response against allergens
JP4072549B2 (ja) 2005-10-31 2008-04-09 株式会社エヌ・ティ・ティ・ドコモ 音声品質確認システム、および音声品質確認方法
AT503530A1 (de) 2006-04-28 2007-11-15 Biomay Ag Polypeptid mit allergenen eigenschaften
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
US20160185831A1 (en) 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
TWI548982B (zh) 2012-03-06 2016-09-11 宏碁股份有限公司 管理方法及相關電腦系統及其電腦程式產品
BR112014031327B1 (pt) * 2012-06-15 2022-02-01 Immunomic Therapeutics, Inc Moléculas de ácido nucleico para o tratamento de alergias
AU2014276484B2 (en) 2013-06-06 2018-01-25 Anergis S.A. Contiguous overlapping peptides for treatment of house dust mites allergy
JP2015200357A (ja) 2014-04-07 2015-11-12 本田技研工業株式会社 車両用動力伝達装置
US20170304432A1 (en) 2014-06-23 2017-10-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
CN107001434B (zh) * 2014-12-02 2021-08-24 大鹏药品工业株式会社 新型粉尘螨蛋白质
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312966B2 (en) * 2018-05-11 2022-04-26 Astellas Pharma Inc. Nucleic acid for treating mite allergy

Also Published As

Publication number Publication date
CO2020013967A2 (es) 2021-02-08
TW202003542A (zh) 2020-01-16
SG11202011163SA (en) 2020-12-30
EP3795688A4 (en) 2022-01-19
PH12020551876A1 (en) 2021-05-31
JPWO2019216394A1 (ja) 2021-05-27
MX2020012057A (es) 2021-01-29
BR112020023041A2 (pt) 2021-02-09
AU2019268022A1 (en) 2020-11-26
CN112105735A (zh) 2020-12-18
WO2019216394A1 (ja) 2019-11-14
CA3099495A1 (en) 2019-11-14
US11312966B2 (en) 2022-04-26
EP3795688A1 (en) 2021-03-24
JOP20200285A1 (ar) 2020-11-09
US20210340549A1 (en) 2021-11-04
MA52634A (fr) 2021-03-24
ZA202006984B (en) 2022-03-30
KR20210007977A (ko) 2021-01-20
AR115379A1 (es) 2021-01-13

Similar Documents

Publication Publication Date Title
CN103687617B (zh) 作为过敏症疫苗的肽载体融合蛋白
EP3677279A1 (en) Conformationally stabilized rsv pre-fusion f proteins
US20110150920A1 (en) Allergy Vaccines Containing Hybrid Polypeptides
ES2891973T3 (es) Partículas de polímero y usos de las mismas
EP2953966B1 (en) Induction of cross-reactive cellular response against rhinovirus antigens
US20220175910A1 (en) Novel influenza antigens
JP2021510169A (ja) アトピー性皮膚炎の治療及び／または予防のためのｉｌ−３１のペプチド免疫原ならびにその製剤
US11312966B2 (en) Nucleic acid for treating mite allergy
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
US8075898B2 (en) Mite allergen
US20210163549A1 (en) Nucleic acid for treating crustacean allergy
JP6327699B2 (ja) 抗マダニワクチン
WO2024055273A1 (zh) 一种狂犬病mRNA疫苗、其制备及应用
BR112016012097A2 (pt) composição vacinal para a prevenção e/ou o tratamento de leishmanioses, peptídeos imunogênicos e processo de obtenção
Saraswati et al. Development of a Tuberculosis Vaccine Seed: Construction of Resuscitation-Promoting Factor B DNA Vaccine and its Expression in Vitro and in Vivo
WO2024068265A2 (en) Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
WO2023161649A1 (en) Rhinovirus vaccine
JP2023182231A (ja) Ｓａｒｓ－ｃｏｖ－２ ｓ糖タンパク質エクトドメインを含むプロテオリポソームおよびワクチンとしてのそれらの使用
WO2018051291A1 (pt) Composição vacinal para proteção contra a leishmaniose tegumentar
KR20190059652A (ko) 일본 뇌염 바이러스 피막 단백질의 돌출 도메인을 포함하는 단백질, 이의 동형이량체, 및 이의 용도

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTELLAS PHARMA INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARUI, TAKANORI;UCHIDA, MASAO;REEL/FRAME:054325/0261

Effective date: 20200907

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION